Jack W. Schuler Purchases 200,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack W. Schuler acquired 200,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were acquired at an average price of $1.17 per share, with a total value of $234,000.00. Following the completion of the purchase, the director now owns 31,094,935 shares of the company’s stock, valued at $36,381,073.95. This trade represents a 0.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Biodesix Price Performance

Shares of NASDAQ BDSX traded up $0.01 during mid-day trading on Thursday, reaching $1.20. 5,212,122 shares of the company were exchanged, compared to its average volume of 203,344. Biodesix, Inc. has a twelve month low of $1.11 and a twelve month high of $2.21. The company’s 50-day simple moving average is $1.59 and its 200-day simple moving average is $1.61. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Friday, November 1st. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, research analysts predict that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Biodesix

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its position in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after buying an additional 21,179 shares during the last quarter. CVI Holdings LLC bought a new stake in shares of Biodesix in the 2nd quarter valued at about $59,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Biodesix during the third quarter valued at approximately $262,000. Opaleye Management Inc. grew its stake in shares of Biodesix by 7.7% in the first quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after purchasing an additional 38,157 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its position in shares of Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after purchasing an additional 310,000 shares during the period. Institutional investors own 20.96% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on BDSX shares. Craig Hallum initiated coverage on Biodesix in a report on Friday, July 26th. They set a “buy” rating and a $3.00 target price for the company. Scotiabank started coverage on Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.